We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$53.6B
AUM Growth
+$2.66B
(+5.2%)
Cap. Flow
+$86.8M
Cap. Flow
% of AUM
0.16%
Top 10 Holdings %
Top 10 Hldgs %
37.17%
Holding
821
New
56
Increased
227
Reduced
258
Closed
253
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$86.2M |
| 2 |
Alcon
ALC
|
+$81.8M |
| 3 |
NVIDIA
NVDA
|
+$76M |
| 4 |
Corning
GLW
|
+$50.4M |
| 5 |
UnitedHealth
UNH
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$67.4M |
| 2 |
Factset
FDS
|
+$62M |
| 3 |
Euronet Worldwide
EEFT
|
+$42.3M |
| 4 |
Bank of America Series L
BAC.PRL
|
+$39.5M |
| 5 |
OPLN
Openlane
OPLN
|
+$31.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.75% |
| 2 | Consumer Discretionary | 17.74% |
| 3 | Financials | 11.65% |
| 4 | Healthcare | 11.2% |
| 5 | Communication Services | 10.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Pegasystems
PEGA
$5.38B
| $8.11M | 0.02% |
+227,812
| New | +$8.11M |
|
352
Outfront Media
OUT
$5.5B
| $7.98M | 0.01% |
+314,273
| New | +$7.66M |
|
353
John Wiley & Sons Class A
WLY
$2.66B
| $7.93M | 0.01% |
172,894
-20,323
| -11% | -$924K |
|
354
Reliance Steel & Aluminium
RS
$21.6B
| $7.89M | 0.01% |
83,339
+21,545
| +35% | +$1.93M |
|
355
ACI Worldwide
ACIW
$5.42B
| $7.74M | 0.01% |
225,488
+65,987
| +41% | +$2.19M |
|
|
FTCH
356
DELISTED
Farfetch Limited Class A Ordinary Shares
FTCH
| $7.72M | 0.01% |
+370,963
| New | +$8.58M |
|
357
Atlanta Braves Holdings Series B
BATRK
$3.21B
| $7.65M | 0.01% |
273,347
+51,698
| +23% | +$1.42M |
|
358
Madison Square Garden
MSGS
$9.39B
| $7.62M | 0.01% |
38,147
+740
| +2% | +$158K |
|
359
Cracker Barrel
CBRL
$1.29B
| $7.31M | 0.01% |
42,812
+8,809
| +26% | +$1.44M |
|
360
Bank OZK
OZK
$5.61B
| $7.2M | 0.01% |
239,244
-13,228
| -5% | -$410K |
|
|
CVET
361
DELISTED
Covetrus, Inc. Common Stock
CVET
| $7.06M | 0.01% |
288,774
+23,401
| +9% | +$674K |
|
362
Digi International
DGII
$3.1B
| $6.92M | 0.01% |
546,142
-10,786
| -2% | -$131K |
|
|
KBAL
363
DELISTED
Kimball International
KBAL
| $6.92M | 0.01% |
396,912
-63,535
| -14% | -$1M |
|
|
NXDT
364
NexPoint Diversified Real Estate Trust
NXDT
$238M
| $6.44M | 0.01% |
340,284
| – | – |
|
|
HOLX
365
DELISTED
Hologic
HOLX
| $6.26M | 0.01% |
130,475
-6,558
| -5% | -$303K |
|
|
SRCI
366
DELISTED
SRC Energy Inc
SRCI
| $6.09M | 0.01% |
1,227,976
+77,391
| +7% | +$421K |
|
367
Comcast
CMCSA
$90B
| $5.93M | 0.01% |
140,151
+57,579
| +70% | +$2.43M |
|
368
Utah Medical Products
UTMD
$225M
| $5.88M | 0.01% |
61,473
-2,381
| -4% | -$200K |
|
369
iShares Russell 1000 Value ETF
IWD
$83.7B
| $5.88M | 0.01% |
46,188
| – | – |
|
|
HAYN
370
DELISTED
Haynes International, Inc.
HAYN
| $5.86M | 0.01% |
184,161
-24,811
| -12% | -$799K |
|
371
United Therapeutics
UTHR
$23.1B
| $5.86M | 0.01% |
+75,010
| New | +$7.01M |
|
372
KLX Energy Services
KLXE
$42.3M
| $5.54M | 0.01% |
54,253
-920
| -2% | -$112K |
|
373
Texas Capital Bancshares
TCBI
$4.32B
| $5.24M | 0.01% |
85,334
-8,450
| -9% | -$514K |
|
|
GCP
374
DELISTED
GCP Applied Technologies Inc.
GCP
| $5.22M | 0.01% |
230,752
-84,627
| -27% | -$2.28M |
|
|
CARO
375
DELISTED
Carolina Financial Corp.
CARO
| $5.13M | 0.01% |
146,039
-5,637
| -4% | -$201K |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q2 2019 Portfolio in Review
As of Q2 2019, Loomis, Sayles & Company held 821 positions worth $53.6B, up 5.2% from $50.9B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Loomis, Sayles & Company's Q2 2019 filing shows 56 new, 227 increased, 258 reduced and 253 closed positions. Its largest new stake was Alcon: 1,393,674 shares worth $86.5M. The largest sale was Novartis, an estimated $67.4M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- Loomis, Sayles & Company's largest Q2 2019 buy was Alcon: 1,393,674 shares worth $86.5M.
- Loomis, Sayles & Company added most to Bristol-Myers Squibb in Q2 2019, an estimated $86.2M increase.
- Loomis, Sayles & Company's biggest Q2 2019 reduction was Novartis, cutting an estimated $67.4M.
- Loomis, Sayles & Company fully exited RingCentral in Q2 2019, selling an estimated $30.4M.
- Loomis, Sayles & Company's ten largest holdings make up 37% of its $53.6B portfolio in Q2 2019.
- Loomis, Sayles & Company opened 56 new positions and closed 253 in Q2 2019.
- Loomis, Sayles & Company's portfolio value rose 5.2% quarter-over-quarter to $53.6B.
Based on Loomis, Sayles & Company's 13F filing for Q2 2019, filed 14 Aug 2019.